SCHEMBL7146866

SCHEMBL7146866

COc1ccc(S(=O)(=O)N(Cc2ccc(Cl)cc2)C2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
MAPK1 P28482 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KCNA5 P22460 1/20 0.54
PSEN1 P49768 2/20 0.54
PSEN2 P49810 2/20 0.54
APH1B Q8WW43 2/20 0.54
NCSTN Q92542 2/20 0.54
APH1A Q96BI3 2/20 0.54
PSENEN Q9NZ42 2/20 0.54
CNR1 P21554 1/20 0.53
CNR2 P34972 1/20 0.53
EP300 Q09472 1/20 0.53
HIF1A Q16665 1/20 0.53
CXCR4 P61073 2/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148857 0.94 MEN1 (0.56) LMNAALDH1A1KCNA5CNR1CNR2
SCHEMBL1682321 0.90 KCNA5 (0.58) LMNAALDH1A1KCNA5CNR1CNR2
SCHEMBL7161846 0.87 ALDH1A1 (0.55) LMNAALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL1682312 0.85 HTT (0.54) ALDH1A1SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL7141761 0.83 ALDH1A1 (0.51) LMNAALDH1A1MAPK1SMN1; SMN2KCNA5
SCHEMBL7166638 0.81 PSEN1 (0.49) LMNAALDH1A1MAPK1SMN1; SMN2KCNA5
SCHEMBL7213083 0.81 NPC1 (0.53) LMNAALDH1A1SMN1; SMN2PSEN1PSEN2
SCHEMBL7141686 0.80 CHRM2 (0.61) LMNAALDH1A1MAPK1CXCR4MEN1
SCHEMBL7141075 0.80 HTT (0.56) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4285152 0.80 SIGMAR1 (0.56) LMNAALDH1A1CXCR4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 LMNA 2941/4885ALDH1A1 1218/4885POLB 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.